Similarly, research by Ozaki et al. demonstrated that RUNX2 attenuates cellular sensitivity to Adriamycin chemotherapy in human osteosarcoma by inhibiting the transcriptional activity of TAp73, a molecule involved in DNA damage response. Here, RUNX2 is linked to osteosarcoma.